{"id":106,"date":"2014-04-23T18:54:17","date_gmt":"2014-04-23T18:54:17","guid":{"rendered":"http:\/\/hfhpulm.com\/info\/?p=106"},"modified":"2014-05-01T19:27:02","modified_gmt":"2014-05-01T19:27:02","slug":"ild-research-trials","status":"publish","type":"post","link":"https:\/\/hfhpulm.com\/info\/?p=106","title":{"rendered":"ILD Research Trials"},"content":{"rendered":"<p><a title=\"More info at Clinicaltrials.gov\" href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01769196?term=IPF%2C+gilead%5C&amp;rank=2\" target=\"_blank\">Simtuzumab<\/a>\u00a0trial (RAINIER, Gilead sponsored) is actively recruiting.<\/p>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">In brief, the study is a multicenter, <\/span><span style=\"color: black;\"><b>phase 2 randomized, double-blind, placebo-controlled trial of a subcutaneous LOXL2 monoclonal antibody in patients with Idiopathic Pulmonary Fibrosis (IPF) up to 180 weeks.<\/b><\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><b>\u00a0<\/b><\/span><\/span><\/div>\n<div><span style=\"color: black; font-family: Calibri, sans-serif; font-size: small; line-height: 1.5em;\">Roel will be screening clinics to look for potentially suitable candidates but would contact you to check if contacting the patient would be acceptable.<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">\u00a0<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">If you have a patient who might be interested in the study, please contact Roel Almario<\/span><span style=\"color: black;\">\u00a0 with the patient&#8217;s name and MRN , so he may discuss the study with the patient.<\/span><\/span><\/div>\n<div><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">We will be reviewing any possible cases\u00a0in Multidisciplinary ILD conference (there is also a central review process once patients have signed informed consent.)<\/span><\/span><\/div>\n<div><\/div>\n<div>\n<div id=\"divIP1\">\n<div id=\"divExp\">\n<div id=\"divBdy\">\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Please let me know if you have any questions.<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">\u00a0<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Thank you,<\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\">Krishna Thavarajah <\/span><\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><br \/>\n<\/span><\/span><\/span><\/span><\/span><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"font-family: Calibri, sans-serif; font-size: small;\"><span style=\"color: black;\"><br \/>\n<\/span><\/span><\/span><\/span><\/div>\n<div><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Krishna Thavarajah, MD MS<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Medical Director, Pulmonary Clinics<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Director, Interstitial Lung Disease Program<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Division of Pulmonary and Critical Care Medicine<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Henry Ford Hospital<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">\u00a0<\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Clinical Assistant Professor <\/span><\/div>\n<div><span style=\"font-family: Calibri, sans-serif; font-size: small;\">Wayne State University School of Medicine<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simtuzumab&nbsp;trial (RAINIER, Gilead sponsored) is actively recruiting. In brief, the study is a multicenter, phase 2 randomized, double-blind, placebo-controlled trial of a subcutaneous LOXL2 monoclonal antibody in patients with Idiopathic Pulmonary Fibrosis (IPF) up to 180 weeks. &nbsp; Roel will be screening clinics to look for potentially suitable candidates but would contact you to check [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[6,8,19],"tags":[],"class_list":["post-106","post","type-post","status-publish","format-standard","hentry","category-clinic","category-ild","category-research"],"modified_by":"Jennings","_links":{"self":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=106"}],"version-history":[{"count":9,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106\/revisions"}],"predecessor-version":[{"id":115,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/106\/revisions\/115"}],"wp:attachment":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}